Linked Life Data

1643637

Source:http://linkedlifedata.com/resource/pubmed/id/1643637

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
16
pubmed:dateCreated
1992-9-10
pubmed:abstractText
The radiation sensitivity of cells isolated directly from surgical specimens of the primary tumor and one to three distant metastases in ten different melanoma patients was measured in vitro using the Courtenay soft agar colony assay. Dose-response curves were fitted to the cell survival data by the method of least squares using the multitarget-single hit and the linear-quadratic models. The ten patients could be divided into three distinct groups. Group I consisted of four patients with radioresistant primary tumors (D0s from 1.38 +/- 0.06 Gy to 1.69 +/- 0.08 Gy). The radiation sensitivity of the metastases (D0s from 1.33 +/- 0.10 Gy to 1.73 +/- 0.06 Gy) was not significantly different from that of the primary tumor in this group; i.e., no heterogeneity was observed. Group II consisted of three patients with radiosensitive primary tumors (D0s from 0.84 +/- 0.06 Gy to 0.91 +/- 0.05 Gy). Heterogeneity was not observed in this group either; i.e., all metastases were radiosensitive (D0s from 0.85 +/- 0.05 Gy to 1.00 +/- 0.06 Gy). Group III consisted of three patients with a heterogeneous disease. The primary tumor of all patients in this group was radiosensitive (D0s from 0.85 +/- 0.05 Gy to 1.03 +/- 0.05 Gy). The most radioresistant metastasis in each patient was significantly (P much less than 0.05) more resistant (D0s from 1.46 +/- 0.06 Gy to 1.56 +/- 0.07 Gy) than the primary tumor. None of the metastases were significantly more radiosensitive than the primary tumor in any patient. These observations suggest that the progression of tumors to increased levels of malignancy includes the increased ability to become radioresistant, and it may be speculated that similar genomic alterations are responsible for the development of the metastatic and the radioresistant tumor cell phenotype. If so, this may have severe implications for the treatment of metastatic malignant melanoma with low linear energy transfer ionizing radiation as well as for the development of predictive assays for tumor treatment sensitivity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4453-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma.
pubmed:affiliation
Institute for Cancer Research, Norwegian Radium Hospital, Montebello, Oslo.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't